- Home
- CRGX vs CRDF Comparison
CRGX vs CRDF Comparison
Compare CRGX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- CRDF
- Stock Information
- Founded
- CRGX 2021
- CRDF 1999
- Country
- CRGX United States
- CRDF United States
- Employees
- CRGX N/A
- CRDF N/A
- Industry
- CRGX
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRGX
- CRDF Health Care
- Exchange
- CRGX Nasdaq
- CRDF Nasdaq
- Market Cap
- CRGX 207.5M
- CRDF 233.5M
- IPO Year
- CRGX 2023
- CRDF N/A
- Fundamental
- Price
- CRGX $4.54
- CRDF $2.44
- Analyst Decision
- CRGX Hold
- CRDF Strong Buy
- Analyst Count
- CRGX 7
- CRDF 6
- Target Price
- CRGX $5.33
- CRDF $10.58
- AVG Volume (30 Days)
- CRGX 1.7M
- CRDF 3.2M
- Earning Date
- CRGX 08-06-2025
- CRDF 07-29-2025
- Dividend Yield
- CRGX N/A
- CRDF N/A
- EPS Growth
- CRGX N/A
- CRDF N/A
- EPS
- CRGX N/A
- CRDF N/A
- Revenue
- CRGX N/A
- CRDF $545,000.00
- Revenue This Year
- CRGX N/A
- CRDF N/A
- Revenue Next Year
- CRGX N/A
- CRDF N/A
- P/E Ratio
- CRGX N/A
- CRDF N/A
- Revenue Growth
- CRGX N/A
- CRDF N/A
- 52 Week Low
- CRGX $3.00
- CRDF $2.09
- 52 Week High
- CRGX $25.45
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- CRGX 59.56
- CRDF 34.95
- Support Level
- CRGX $4.45
- CRDF $2.39
- Resistance Level
- CRGX $4.51
- CRDF $2.50
- Average True Range (ATR)
- CRGX 0.04
- CRDF 0.21
- MACD
- CRGX -0.00
- CRDF -0.03
- Stochastic Oscillator
- CRGX 76.00
- CRDF 9.93
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.